SOURCE: SAFE-BioPharma, Inc.

June 27, 2005 08:30 ET

SAFE-BioPharma Association Announces Hiring of CEO

SAFE Commences Operations and Selects CEO

WHITEHOUSE STATION, NJ -- (MARKET WIRE) -- June 27, 2005 -- SAFE-BioPharma Association, an organization dedicated to managing a digital signature standard for worldwide use by the healthcare industry, today announced that it has appointed Mollie Shields-Uehling as president and chief executive officer of the Association. Ms. Shields-Uehling brings a wealth of industry expertise to SAFE-BioPharma Association, with more than 20 years of international trade and biopharmaceutical industry experience.

"I am delighted to assume leadership of SAFE-BioPharma Association at such a key point in its development and look forward to establishing SAFE as the industry standard," said Ms. Shields-Uehling. "The SAFE standard eliminates today's multiple, complicated eSignature systems with their required duplicative paper signatures. It provides a single, rapid, cost-saving standard for secure identity management in a new era in healthcare research, discovery, and delivery."

Ms. Shields-Uehling will lead the company and its members through the next critical phase of development of the standard, implementation and use, and network growth.

"We are pleased to welcome Mollie as SAFE BioPharma Association's new CEO," said Gary Secrest, chairman of the board and director, Worldwide Information Security, Johnson & Johnson. "Mollie will provide us strong leadership that will extend the successful launch of the standard, the establishment of the non-profit Company, and the implementation of the pre-production phase of the SAFE Bridge Certification Authority."

Prior to joining SAFE-BioPharma Association as CEO, Ms. Shields-Uehling was principal of Shields-Uehling Associates, an international public affairs consultancy. She previously served in various leadership positions with Bristol-Myers Squibb, Wyeth, the International AIDS Vaccine Initiative (IAVI), and in the White House Office of the U.S. Trade Representative and the U.S. Foreign Commercial Service.

SAFE participants include: Abbott Laboratories*, Amgen, Astra-Zeneca*, Bristol-Myers Squibb*, The European Federation of Pharmaceutical Industries and Associations (EFPIA), European Medicines Evaluation Agency (EMEA), the U.S. Food and Drug Administration (FDA), Glaxo-Smith Kline*, Johnson & Johnson*, Merck*, National Cancer Institute, INC Research, Pfizer*, Procter and Gamble*, Pharmaceutical Research and Manufacturers of America (PhRMA), Sanofi-Aventis*, Schulman Associates, TAP Pharmaceuticals, Western Institutional Review Board. (* denotes founding member)

About SAFE

SAFE (www.safe-biopharma.org) is an identity assurance standard developed to reduce the complexity and cost of managing paper for the healthcare community. The SAFE standard consists of operational policies and technical specifications for the distribution of identity credentials. SAFE signatures are being used in business-to-business and business-to-regulator transactions for access control, legally enforceable and regulatory compliant digital signatures. The standard is managed and maintained under the SAFE-BioPharma Association, a not-for-profit entity created to support the management and maintenance of the standard. The company offers a variety of membership options, and business partner options for organizations seeking to join or integrate SAFE into their products.

Contact Information

  • For more information regarding SAFE, contact:
    Jill Ryan or Bree Clidence
    Stauch Vetromile & Mitchell
    401-438-0614
    Email Contact or Email Contact